NEW YORK (GenomeWeb News) – Sangamo BioSciences today announced that it has entered into a licensing agreement with Palo Alto, Calif.-based Open Monoclonal Technologies, under which OMT obtained non-exclusive, worldwide rights to develop transgenic animals using Sangamo’s proprietary zinc finger DNA-binding technology.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.